{"id":93757,"date":"2026-05-21T13:18:54","date_gmt":"2026-05-21T07:48:54","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=93757"},"modified":"2026-05-21T13:18:57","modified_gmt":"2026-05-21T07:48:57","slug":"suven-pharmaceuticals-analyst-review-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/","title":{"rendered":"Suven Pharmaceuticals Analyst Review May 2026"},"content":{"rendered":"<p>This <strong><a href=\"https:\/\/univest.in\/user\/stocks\/cohance\/suven-pharmaceuticals-ltd-share-price-today\">Suven Pharmaceuticals<\/a> analyst review<\/strong> for May 2026 covers the key data investors need for SUVENPHAR at its current price of Rs 1,250. Suven Pharmaceuticals (NSE: SUVENPHAR) is a pharmaceutical CDMO company with a market capitalisation of approximately Rs 8,500 crore, specialising in CNS (central nervous system) and specialty molecule synthesis. The analyst consensus target of Rs 1,550 implies meaningful upside, and this <strong>Suven Pharmaceuticals analyst review<\/strong> examines technical levels, business performance, valuation, and key risks for SUVENPHAR through FY27.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#Suven_Pharmaceuticals_Company_Snapshot_May_2026\" title=\"Suven Pharmaceuticals Company Snapshot May 2026\">Suven Pharmaceuticals Company Snapshot May 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#Analyst_Insight_in_This_Suven_Pharmaceuticals_Analyst_Review\" title=\"Analyst Insight in This Suven Pharmaceuticals Analyst Review\">Analyst Insight in This Suven Pharmaceuticals Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#Technical_Analysis_in_This_Suven_Pharmaceuticals_Analyst_Review\" title=\"Technical Analysis in This Suven Pharmaceuticals Analyst Review\">Technical Analysis in This Suven Pharmaceuticals Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#Key_Support_and_Resistance_Levels\" title=\"Key Support and Resistance Levels\">Key Support and Resistance Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#Business_Segment_Analysis\" title=\"Business Segment Analysis\">Business Segment Analysis<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#CNS_Molecule_CDMO_Core_High-Value_Segment\" title=\"CNS Molecule CDMO (Core High-Value Segment)\">CNS Molecule CDMO (Core High-Value Segment)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#Specialty_API_Custom_Synthesis\" title=\"Specialty API Custom Synthesis\">Specialty API Custom Synthesis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#Commercial_Manufacturing_Scale-Up_Services\" title=\"Commercial Manufacturing Scale-Up Services\">Commercial Manufacturing Scale-Up Services<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#Valuation_in_This_Suven_Pharmaceuticals_Analyst_Review\" title=\"Valuation in This Suven Pharmaceuticals Analyst Review\">Valuation in This Suven Pharmaceuticals Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#Trade_Outlook_for_Suven_Pharmaceuticals\" title=\"Trade Outlook for Suven Pharmaceuticals\">Trade Outlook for Suven Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#Key_Risks_for_Suven_Pharmaceuticals_in_FY27\" title=\"Key Risks for Suven Pharmaceuticals in FY27\">Key Risks for Suven Pharmaceuticals in FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#Conclusion_Suven_Pharmaceuticals_Analyst_Review_Verdict_for_2026\" title=\"Conclusion: Suven Pharmaceuticals Analyst Review Verdict for 2026\">Conclusion: Suven Pharmaceuticals Analyst Review Verdict for 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#Frequently_Asked_Questions_Suven_Pharmaceuticals_Analyst_Review_2026\" title=\"Frequently Asked Questions: Suven Pharmaceuticals Analyst Review 2026\">Frequently Asked Questions: Suven Pharmaceuticals Analyst Review 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#What_is_the_analyst_target_for_Suven_Pharmaceuticals_in_2026\" title=\"What is the analyst target for Suven Pharmaceuticals in 2026?\">What is the analyst target for Suven Pharmaceuticals in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#Is_Suven_Pharmaceuticals_a_good_investment_at_Rs_1250\" title=\"Is Suven Pharmaceuticals a good investment at Rs 1,250?\">Is Suven Pharmaceuticals a good investment at Rs 1,250?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#What_is_Suven_Pharmaceuticalss_52-week_high_and_low\" title=\"What is Suven Pharmaceuticals&#8217;s 52-week high and low?\">What is Suven Pharmaceuticals&#8217;s 52-week high and low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#What_are_the_key_risks_for_Suven_Pharmaceuticals\" title=\"What are the key risks for Suven Pharmaceuticals?\">What are the key risks for Suven Pharmaceuticals?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/suven-pharmaceuticals-analyst-review-2026\/#Where_can_I_track_live_data_for_Suven_Pharmaceuticals\" title=\"Where can I track live data for Suven Pharmaceuticals?\">Where can I track live data for Suven Pharmaceuticals?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Suven_Pharmaceuticals_Company_Snapshot_May_2026\"><\/span><strong>Suven Pharmaceuticals Company Snapshot May 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Suven Pharmaceuticals&#8217; CDMO services for global pharma innovators in CNS, oncology, and metabolic diseases provide high-value, long-duration service contracts. Zero-debt and above 40 percent EBITDA margins underpin quality. The table below summarises the key data referenced in this <strong>Suven Pharmaceuticals analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>SUVENPHAR<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceuticals &#8211; CDMO<\/td>\n<\/tr>\n<tr>\n<td>CMP (May 2026)<\/td>\n<td>Rs 1,250<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 1,650<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 1,050<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 8,500 Crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing P\/E<\/td>\n<td>45x<\/td>\n<\/tr>\n<tr>\n<td>Analyst Consensus Target<\/td>\n<td>Rs 1,550<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 1,900<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 1,000<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Analyst_Insight_in_This_Suven_Pharmaceuticals_Analyst_Review\"><\/span><strong>Analyst Insight in This Suven Pharmaceuticals Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Associate Director <strong>Kunal Singla<\/strong> suggests watching Suven Pharmaceuticals closely in May 2026. At Rs 1,250, Kunal Singla flags Pharmaceuticals &#8211; CDMO sector dynamics as the primary driver for SUVENPHAR&#8217;s near-term price action. He notes support in the Rs 1071 to Rs 1188 zone and flags any sustained close above Rs 1325 as a positive signal. Kunal Singla&#8217;s perspective on Suven Pharmaceuticals adds professional analysis to this <strong>Suven Pharmaceuticals analyst review<\/strong> and is not a buy recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Analysis_in_This_Suven_Pharmaceuticals_Analyst_Review\"><\/span><strong>Technical Analysis in This Suven Pharmaceuticals Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 1,250, SUVENPHAR is trading within its 52-week band of Rs 1,050 to Rs 1,650. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.<\/p>\n<p>Near-term support is identified in the Rs 1071 to Rs 1188 band while resistance is seen in the Rs 1325 to Rs 1400 zone. A sustained move above Rs 1325 could open the path toward the analyst consensus target of Rs 1,550 as identified in this <strong>Suven Pharmaceuticals analyst review<\/strong>.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen the best stocks on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Support_and_Resistance_Levels\"><\/span><strong>Key Support and Resistance Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Support Zone:<\/strong> Rs 1071 to Rs 1188 &#8211; investors tracking this <strong>Suven Pharmaceuticals analyst review<\/strong> should watch for stabilisation or a bounce in this range as a potential accumulation signal for SUVENPHAR.<\/li>\n<li><strong>Resistance Zone:<\/strong> Rs 1325 to Rs 1400 &#8211; a sustained close above Rs 1325 would be a positive breakout signal worth flagging in this <strong>Suven Pharmaceuticals analyst review<\/strong>.<\/li>\n<li><strong>Medium-Term Target:<\/strong> The analyst consensus of Rs 1,550 represents the base-case upside scenario in this <strong>Suven Pharmaceuticals analyst review<\/strong>.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Business_Segment_Analysis\"><\/span><strong>Business Segment Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"CNS_Molecule_CDMO_Core_High-Value_Segment\"><\/span><strong>CNS Molecule CDMO (Core High-Value Segment)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the primary revenue and margin driver for Suven Pharmaceuticals, directly supporting the earnings trajectory toward the consensus target of Rs 1,550.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Specialty_API_Custom_Synthesis\"><\/span><strong>Specialty API Custom Synthesis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This segment adds scale and diversification to Suven Pharmaceuticals&#8217;s business model and is a meaningful EPS contributor through FY27 and FY28.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Commercial_Manufacturing_Scale-Up_Services\"><\/span><strong>Commercial Manufacturing Scale-Up Services<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This represents the medium-term growth frontier for Suven Pharmaceuticals and a key re-rating catalyst for the stock over the next 12 to 24 months.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_in_This_Suven_Pharmaceuticals_Analyst_Review\"><\/span><strong>Valuation in This Suven Pharmaceuticals Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 1,250, Suven Pharmaceuticals trades at a trailing P\/E of 45x. This <strong>Suven Pharmaceuticals analyst review<\/strong> presents three scenarios: a bull case of Rs 1,900 on strong earnings delivery, a base case of Rs 1,550 at analyst consensus, and a bear case of Rs 1,000 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this <strong>Suven Pharmaceuticals analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target Price<\/th>\n<th>Key Condition<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 1,900<\/td>\n<td>Strong earnings delivery and sector re-rating<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Consensus)<\/td>\n<td>Rs 1,550<\/td>\n<td>Moderate growth, analyst consensus estimate<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 1,000<\/td>\n<td>Earnings miss or macro headwinds<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Trade_Outlook_for_Suven_Pharmaceuticals\"><\/span><strong>Trade Outlook for Suven Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Based on the technical and fundamental analysis in this <strong>Suven Pharmaceuticals analyst review<\/strong>, investors might watch SUVENPHAR near the support zone of Rs 1071 to Rs 1188 for potential opportunities. A flag above Rs 1325 could suggest improving momentum toward Rs 1,550. This article uses watch-and-flag language only and does not constitute a trade recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Suven_Pharmaceuticals_in_FY27\"><\/span><strong>Key Risks for Suven Pharmaceuticals in FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A well-rounded <strong>Suven Pharmaceuticals analyst review<\/strong> must assess downside risks. Key risks for Suven Pharmaceuticals include a macro slowdown affecting Pharmaceuticals &#8211; CDMO sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in SUVENPHAR.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and expert research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_Suven_Pharmaceuticals_Analyst_Review_Verdict_for_2026\"><\/span><strong>Conclusion: Suven Pharmaceuticals Analyst Review Verdict for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This <strong>Suven Pharmaceuticals analyst review<\/strong> concludes that at Rs 1,250, SUVENPHAR offers a defined risk-reward with a consensus target of Rs 1,550. The 52-week range of Rs 1,050 to Rs 1,650 provides context on the current entry point. Use this <strong>Suven Pharmaceuticals analyst review<\/strong> as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on SUVENPHAR.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_Suven_Pharmaceuticals_Analyst_Review_2026\"><\/span><strong>Frequently Asked Questions: Suven Pharmaceuticals Analyst Review 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_analyst_target_for_Suven_Pharmaceuticals_in_2026\"><\/span><strong>What is the analyst target for Suven Pharmaceuticals in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The analyst consensus target is Rs 1,550, with a bull case of Rs 1,900 and a bear case of Rs 1,000. This <strong>Suven Pharmaceuticals analyst review<\/strong> recommends monitoring Q1 FY27 earnings for confirmation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Suven_Pharmaceuticals_a_good_investment_at_Rs_1250\"><\/span><strong>Is Suven Pharmaceuticals a good investment at Rs 1,250?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 1,250 with a P\/E of 45x and a consensus target of Rs 1,550, this <strong>Suven Pharmaceuticals analyst review<\/strong> is constructive for medium to long-term investors in the Pharmaceuticals &#8211; CDMO sector. Always consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Suven_Pharmaceuticalss_52-week_high_and_low\"><\/span><strong>What is Suven Pharmaceuticals&#8217;s 52-week high and low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 52-week high is Rs 1,650 and the 52-week low is Rs 1,050. At Rs 1,250, SUVENPHAR is positioned within this range as noted in this <strong>Suven Pharmaceuticals analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_for_Suven_Pharmaceuticals\"><\/span><strong>What are the key risks for Suven Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals &#8211; CDMO sector as assessed in this <strong>Suven Pharmaceuticals analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_live_data_for_Suven_Pharmaceuticals\"><\/span><strong>Where can I track live data for Suven Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track Suven Pharmaceuticals&#8217;s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this <strong>Suven Pharmaceuticals analyst review<\/strong>.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suven Pharmaceuticals analyst review 2026: CMP Rs 1,250, MCap Rs 8,500 Cr, PE 45x. Pharmaceuticals &#8211; CDMO sector outlook and technical levels. May 2026.<\/p>\n","protected":false},"author":28,"featured_media":93989,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-93757","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1779349740:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["82"],"rank_math_title":["Suven Pharmaceuticals Analyst Review 2026"],"rank_math_description":["Suven Pharmaceuticals analyst review 2026: CMP Rs 1,250, MCap Rs 8,500 Cr, PE 45x. Pharmaceuticals - CDMO sector outlook and technical levels. May 2026."],"rank_math_focus_keyword":["Suven Pharmaceuticals Analyst Review"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["93989"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["12747"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/21131837\/Suven-Pharmaceuticals-Analyst-Review.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/93757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=93757"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/93757\/revisions"}],"predecessor-version":[{"id":93990,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/93757\/revisions\/93990"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/93989"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=93757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=93757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=93757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}